The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients

Acta Haematologica

Volumn 111, Issue 3, 2004, Pages 175-180

  Potter, M ^a   Donnelly, J P ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fungal infection, systemic; Itraconazole; Malignancy, haematological; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN A; CYTARABINE; DRUG CARRIER; DRUG METABOLITE; FLUCONAZOLE; FLUCYTOSINE; FLUDARABINE; HYDROXYITRACONAZOLE; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LIPOSOME; NYSTATIN; PYRROLE DERIVATIVE; TACROLIMUS; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; AUTONOMIC NEUROPATHY; BONE MARROW TOXICITY; BRAIN INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; INFECTION RATE; INFECTION RISK; LUNG ASPERGILLOSIS; MAINTENANCE THERAPY; META ANALYSIS; MYCOSIS; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

DRUG INTERACTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; ITRACONAZOLE; MYCOSES;

EID: 1842613638     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076530     Document Type: Conference Paper

References (29)

1. Potter M: Systemic fungal infections in immunocompromised patients. Curr Opin Infect Dis 1999;12:359-363.
2. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001;32:358-366.
3. Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, Cleeren M, Wostenborghs R, De Beule K: Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001;45:981-985.
4. Prentice AG, Copplestone JA, Hamon MD, Rule S, Cavanagh J, Schey S: Intravenous itraconazole can replace oral solution in Aspergillus prophylaxis: Pharmacokinetic data from patients treated for haematological malignancy (abstract P633). Presented at EBMT, Bone Marrow Transplantation, March 2000, 25 S1.
5. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-3246.
6. Goodman JL, Winston DJ, Greenfield RA, Chandraseka PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.
7. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.
8. Marr KA: Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT recipients: Results of a randomized trial (Blood 100, abstract 806). Presented at ASH, Philadelphia, 2002.
9. Menichetti F, Del Favero A, Martino R: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies. Clin Infect Dis 1999;28:250-255.
10. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K: Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, doubleblind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:1887-1893.
11. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901-911.
12. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-713.
13. Glasmacher A: Meta-analysis of itraconazole antifungal prophylaxis trials reveals a dose-response effect for the prevention of invasive fungal infections, including Aspergillus, in neutropenic patients. Blood 2002;100:216a.
14. Prentice HG, Kibbler CC, Prentice AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2003;110:273-284.
15. Bohme A, Ganser A, Hoelzer D: Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-312.
16. Murphy JA, Ross LM, Gibson BE: Vincristine toxicity in five children with acute lymphoblastic leukaemia (letter). Lancet 1995;346:443.
17. Itraconazole: Cautions; in: British National Formulary. London, British Medical Association, 2001, p 294.
18. Wald A, Leisenring W, van Burik JA, Bowden RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466.
19. Back DJ, Tjia JF: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-626.
20. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234.
21. Boogaerts MA, Winston DJ, Bow EJ: A randomized, controlled trial of intravenous and oral itraconazole versus intravenous amphotericin B for empirical antifungal therapy of persistent fever in neutropenic cancer patients receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001;135:412-422.
22. Caillot D, Bassari H, McGeer A: Intravenous followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematological malignancies, chronic granulomatous disease or AIDS. Clin Infect Dis 2001;33:83-90.
23. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S: Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003;121:448-457.
24. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts MA: Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297-1306.
25. Viscoli C, Machetti M, Gazzola P, De Maria A, Paola D, Van Lint MT, Gualandi F, Truini M, Bacigalupo A: Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002;40:1496-1499.
26. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
27. Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 2001;21:149S-164S.
28. Popp AI, White MH, Quadri T, Walshe L, Armstrong D: Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. Int J Infect Dis 1999;3:157-160.
29. Rubin MA, Carroll KC, Cahill BC: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2003;34:1160-1161.